Pablo Herrero-Puente Selected Research

Pablo Herrero-Puente Research Topics

15	Heart Failure 12/2023 - 02/2015
1	Atrial Fibrillation 12/2023
1	COVID-19 01/2022
1	Iron Deficiencies 10/2020
1	Hypotension (Low Blood Pressure) 08/2020
1	Infections 01/2020
1	Chronic Obstructive Pulmonary Disease (COPD) 10/2019
1	Dyspnea (Shortness of Breath) 10/2019
1	Heart Diseases (Heart Disease) 06/2019
1	Cardiomyopathies (Cardiomyopathy) 09/2018
1	Hypertension (High Blood Pressure) 01/2018
1	Peripheral Arterial Disease 01/2018
1	Pulmonary Edema 11/2015
1	Disease Progression 02/2015
1	Hyponatremia 06/2014
1	Kidney Diseases (Kidney Disease) 06/2014
1	Respiratory Insufficiency (Respiratory Failure) 06/2014

3	TroponinIBA 06/2020 - 06/2014
2	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 08/2020 - 06/2019
2	Troponin T (Troponin T1)IBA 06/2020 - 10/2019
2	Natriuretic PeptidesIBA 10/2019 - 06/2014
2	pro-brain natriuretic peptide (1-76)IBA 10/2019 - 09/2018
1	Digoxin (Digitek)FDA LinkGeneric 12/2023
1	Vitamin D FDA LinkGeneric 01/2022
1	Cholecalciferol (Vitamin D3)FDA Link 01/2022
1	Nitroglycerin (Dynamite)FDA LinkGeneric 12/2021
1	ferric carboxymaltoseIBA 10/2020
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2020
1	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2019
1	trans-crotonin (CTN)IBA 06/2019
1	Mineralocorticoid Receptor AntagonistsIBA 06/2019
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 06/2019
1	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2019
1	SodiumIBA 09/2018
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2018
1	Galectin 3 (LGALS3)IBA 12/2017
1	Morphine (MS Contin)FDA LinkGeneric 10/2017
1	NitratesIBA 11/2015